Background--During myocardial ischemia/reperfusion (I/R), a large amount of reactive oxygen species (ROS) is produced. In particular, overproduction of hydrogen peroxide (H 2 O 2 ) is considered to be a main cause of I/R-mediated tissue damage. We generated novel H 2 O 2 -responsive antioxidant polymer nanoparticles (PVAX and HPOX) that are able to target the site of ROS overproduction and attenuate the oxidative stress-associated diseases. In this study, nanoparticles were examined for their therapeutic effect on myocardial I/R injury.
R
eactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide (H 2 O 2 ), and hydroxyl radical, are chemically reactive compounds that oxidize proteins, nucleic acids, and lipids. 1 ROS are derived from molecular oxygen and formed as a natural by-product of aerobic metabolism. Under normal circumstances, ROS are important secondary messengers involved in multiple cellular signaling. The levels of ROS are controlled by antioxidants, which keep them in the picomolar range. 2 However, accumulation of ROS over extended periods of time causes oxidative stress, which triggers cell death and irreversible tissue damage. Many diseases are associated with ROS-mediated oxidative stress, including cancer, neurodegenerative diseases, and I/R injury. In particular, ROS overproduction is one of the central pathological mechanisms in cardiac I/R injury. 3 It is well accepted that a large amount of ROS is generated immediately after reperfusion and may elicit cell death, such as apoptosis. 4, 5 Among various ROS, superoxide anion and H 2 O 2 are particularly important in cardiomyocytes. Superoxide anion is short-lived and is rapidly reduced to H 2 O 2 spontaneously or by superoxide dismutase. In contrast, H 2 O 2 has a longer biological life span and is easily diffusible within and between cells. 6 A massive accumulation of H 2 O 2 is known to be the critical pathogenic mechanism of I/R-induced tissue damage by releasing proinflammatory cytokines and triggering apoptosis. 7 In this context, targeting the site of H 2 O 2 overproduction and rapid reduction of excessive ROS are promising strategies to alleviate myocardial I/R injury. 4, 8 Numerous antioxidants have been explored as therapeutic agents for I/R injuries. 8 Various formulations of nanoparticles have also been developed as drug carriers that could release the drug payloads in spatial and temporal-specific manners to enhance their therapeutic efficacy. 9, 10 Recently, we have developed H 2 O 2 -responsive antioxidant copolyoxalates containing hydroxybenzyl alcohol (HBA) (HPOX) and vanillyl alcohol (VA) (PVAX) that could serve as therapeutic agents for ROS-associated diseases. 11, 12 PVAX or HPOX was synthesized using naturally occurring compounds with intrinsic antioxidant and anti-inflammatory activities, VA and HBA, respectively. These polymers were chemically engineered to possess H 2 O 2 -responsive peroxalate ester linkages and therapeutic agents in their backbone. These antioxidant polymeric prodrug nanoparticles have a mean diameter of~400 nm. They could be rapidly activated by H 2 O 2 at the site of ROS generation. They prevent the I/Rinduced injuries by exerting antioxidant, anti-inflammatory, and antiapoptotic effects. 11, 12 Their therapeutic effects were explained by the synergistic effects of H 2 O 2 -scavening peroxalate ester bonds with antioxidant and anti-inflammatory effects of therapeutic agents (VA or HBA). 11, 12 However, direct comparison between HPOX and PVAX has not been made, and their potential as therapeutic agents for myocardial I/R injury has not been evaluated. The objective of the present work is to evaluate the potential of antioxidant copolyoxalates as therapeutic agents for myocardial I/R injury. We first used a mouse model of hind limb I/R to directly compare their therapeutic effects on I/R injury. The direct comparison studies revealed that PVAX has superior therapeutic and protective effects against I/R compared to HPOX. We then utilized a mouse cardiac I/R injury model to determine the potential of PVAX as a therapeutic agent.
Methods
Synthesis of PVAX and HPOX 
Preparation and Administration of PVAX and HPOX Nanoparticles
HPOX or PVAX nanoparticles were generated using an emulsion/solvent evaporation method as previously reported. 11, 12 In brief, HPOX or PVAX dissolved in DCM was added to 5 mL of 10% (w/v) polyvinyl alcohol (PVA) solution. The mixtures were sonicated and then homogenized to form fine oil/water emulsions. The emulsion was transferred to a 20-mL PVA (1% w/v) solution and homogenized for another 1 minute. The remaining solvent was removed using a rotary evaporator. The particles were then centrifuged and washed with deionized water 3 times to remove the residual PVA. The suspension was then frozen in liquid nitrogen and lyophilized to produce freeflowing particles. One milligram of HPOX or PVAX was dissolved in 1 mL of phosphate-buffered saline (PBS). PVAX or HPOX was administered into the gastrocnemius muscles in hind limb I/R injury model. PVAX was administered intraperitoneally in the cardiac I/R injury model. 
Animal Surgeries
Animal surgeries were performed in 12-to 13-week-old male C57/B mice (Charles River Laboratory, Wilmington, MA). For hind limb I/R surgery, a femoral artery was identified and tied around a specialized 30G catheter with a 7-0 silk suture after mice were anesthetized with inhalant isoflurane (2%). Full anesthesia was verified with toe pinching. The animal remained under anesthesia for a specified duration of ischemia. Reperfusion was achieved by cutting the suture and reestablishing arterial blood flow. 
Cardiac Functional Analysis
Cardiac function was measured in mice using the left ventricle (LV) pressure-volume loop and echocardiography 2 weeks after I/R surgery or sham control. After 2% isoflurane inhalant anesthesia, the pressure-volume parameters were measured using a 1.4Fr microtip pressure-volume catheter (ScisenseInc, Ontario, Canada). The catheter was first inserted into the right common carotid artery and then gently advanced into the LV to obtain LV hemodynamic parameters. Data were recorded using a Powerlab system (ADInstruments, Colorado Springs, CO). Beat-by-beat pressure-volume parameters including heart rate (HR), stroke volume (SV), stroke work (SW), and cardiac output (CO) were measured and analyzed using CardioSoft Pro software (CardioSoft, Houston, TX). Transthoracic echocardiography was performed using a Vevo2100 echocardiogram (VisualSonics, Toronto, Canada) with a MS400 (18-38 MHz) transducer at baseline and 2 weeks after I/R. Two-dimensional guided M-mode images were recorded.
Infarct Size Determination
Infarct size was measured 24 hours after I/R surgery as described previously. 13 After thoracotomy, the LAD was religated, and 50 lL green fluorescent FluoSpheres (Molecular Probe, Carlsbad, CA) was injected into the LV of the heart to delineate the area at risk (FluoSpheres-negative area). The heart was then excised, fixed, and sectioned into 1-mm perpendicular sections. Sections were stained with 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Chemical, St. Louis, MO) solution to determine the infarcted myocardium (TTCnegative area). The infarction area (IA) and the area at risk (AAR) were determined for each slice using a computer planimetry and NIH Image software.
Reverse Transcriptase-Polymerase Chain Reaction Analysis for mRNA Expression
Heart tissues were collected for molecular analysis after I/R. Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed as described previously. 11, 12 The mRNA expression levels were analyzed by RT-PCR using specific primers. Ribosomal 18S primers acted as internal controls, and all RT-PCR signals were normalized to the 18S signal of the corresponding RT product to eliminate the measurement error from uneven sample loading and to provide a semiquantitative measure of the relative changes in gene expression. The PCR primers used in this study are listed below: sense TNF-a, 5-CCTCAG CCTCTTCTCCTTCCT-3; antisense TNF-a, 5-GGTGTGGGTGAGGAGCA-3; sense MCP-1, 5-CCC CACTCACCTGCTGCTACT-3; antisense MCP-1, 5-GCATCA-CAGTCCGAGTCACA -3; sense 18S, 5-GTTATGGTTCCTTTGT CGCTCGCTC-3, anti-sense 18S, 5-TCGGCCCGAGGTTATCTA-GAGTCAC-3.
Caspase-3 and PARP Activity Assay
The activity of caspase-3 was determined with a colorimetric assay kit (R&D Systems, Minneapolis, MN) as described previously. 11, 12 Briefly, protein samples were added to the substrates of Acetyl-Asp-Glu-Val-Asp-p-nitroanilide. The enzyme-catalyzed release of p-nitroanilide was measured at 405 nm. For PARP activity assay, activity was measured at 450 nm for incorporation of biotinylated poly(ADP-ribose) onto histone-coated proteins in a plate using a colorimetric assay kit (R&D Systems, Minneapolis, MN) as described previously.
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Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling Staining and Dihydroethidium Staining
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining was performed using an in situ cell death detection kit, fluorescein (Roche Applied Science, Indianapolis, IN) as described previously. 11, 12 To distinguish cardiomyocyte from noncardiomyocyte nuclei, we used triple staining for nuclei (4
staining), apoptotic nuclei (TUNEL staining), and cardiomyocytes (a-actinin staining) and analyzed the stained sections using confocal microscopy. For dihydroethidium (DHE) staining, tissue sections were incubated with 5 lmol/L of DHE (Sigma-Aldrich, St. Louis, MO) at 37°C for 30 minutes in a humidified chamber protected from light, and then DAPI was applied. Images were acquired by confocal fluorescent microscope.
Western Immunoblot
NADPH oxidase 2 (NOX2) and NOX4 proteins were probed with an anti-NOX2 and anti-NOX4 rabbit monoclonal antibody (Abcam, Cambridge, MA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control for loading. Resulting bands were quantified as optical density (OD)9band area by ImageJ analysis system and recorded as arbitrary units.
Primary Adult Rat Ventricular Cardiomyocyte Culture
The primary culture of adult rat ventricular cardiomyocytes (ARVC) was prepared from the hearts of female rats as described previously. 14 Rat hearts were extracted after anesthesia with inhalant isoflurane (2%). For cell viability, a 3-(4,5-dimethylthiazil-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed according to the manufacturer's instructions (Sigma, St. Louis, MO), and as previously reported.
14 Briefly, cells were treated with MTT for 3 hours.
Formed formazan crystals were dissolved with dimethyl sulfoxide while plates were agitated on a shaker for 30 minutes in the dark. Absorbance was measured at 570 nm with a reference wavelength at 690 nm. Figure 1C) . However, PVAX nanoparticles showed higher emission intensity than HPOX nanoparticles. In addition, we compared the antioxidant and antiapoptotic activities of PVAX and HPOX nanoparticles in vitro. RAW264.7 cells were stimulated with PMA to induce ROS generation ( Figure 1D ). The generation of ROS in PMAstimulated cells was investigated using a ROS probe, DCFH-DA, which becomes fluorescent on activation by ROS such as H 2 O 2 and hydroxyl radical. Both HPOX and PVAX showed decreases in their fluorescent intensity compared to the PMA alone, but PVAX induced a greater reduction in the fluorescence intensity than HPOX, indicating that PVAX have more inhibitory effects on PMA-induced ROS generation. Antiapoptotic effects of both nanoparticles on H 2 O 2 -stimulated cells were evaluated by staining with annexin V-FITC as a marker of apoptosis ( Figure 1E ). PVAX again exerted stronger antiapoptotic activity in H 2 O 2 -stimulated cells than HPOX.
Comparison of PVAX and HPOX Using a Mouse Model of Hind Limb I/R Injury
To compare antiapoptotic and anti-inflammatory activities of HPOX and PVAX nanoparticles, a mouse model of hind limb I/ R injury was used. I/R injury was induced by tying the femoral artery with a suture for 1 hour, followed by reperfusion. PVAX and HPOX (50 and 100 lg) were directly injected just distal to the ligation site, and their therapeutic effects were compared by measuring the level of anti-inflammatory and antiapoptotic activities. The activities of caspase-3 and polyADP ribose polymerase (PARP) were analyzed to measure the level of apoptosis. I/R injury caused significant elevation of caspase-3 and PARP activities (Figure 2A and 2B ). Both PVAX and HPOX nanoparticles significantly decreased the activities of caspase-3 and PARP in a dose-dependent manner. However, PVAX showed significantly greater antiapoptotic activity than HPOX. The levels of tumor necrosis factor-a (TNF-a) and monocyte chemotactic protein-1 (MCP-1) were evaluated as markers of inflammation. Both nanoparticles significantly suppressed I/R-induced expression of mRNA of TNF-a and MCP-1 ( Figure 2C through 2E) . In particular, 100 lg of PVAX almost completely suppressed the expression of mRNA of TNF-a and MCP-1. In addition, H&E staining demonstrated that muscle damage caused by I/R injury was significantly inhibited by PVAX ( Figure 2F ). Based on these findings, we conclude that PVAX has superior anti-inflammatory and antiapoptotic activities against ROS-associated diseases than HPOX. Thus, PVAX was selected as a therapeutic agent for subsequent cardiac I/R injury experiments.
Therapeutic Effects of PVAX Nanoparticles on H 2 O 2 -Stimulated Adult Rat Cardiomyocytes
First, antioxidant and anti-inflammatory activities of PVAX nanoparticles were studied using the primary culture of adult rat cardiomyocytes (ARVC). To test protective effect of PVAX against oxidative stress in vitro, we examined H 2 O 2 -induced blocked the H 2 O 2 -induced TNF-a, MCP-1, NOX2, and NOX4 activation.
Therapeutic Effects of PVAX Nanoparticles on Cardiac Functions After I/R Injury
Because reperfusion of the ischemic myocardium triggers further production of ROS causing myocardial dysfunction, we evaluated the beneficial effects of H 2 O 2 -responsive PVAX nanoparticles using a mouse model of cardiac I/R injury. Previous studies have demonstrated that cardiac function is decreased 2 weeks after I/R injury. 16=18 Thus, the cardiac functions were evaluated 2 weeks after cardiac I/R injury using PV loop analysis and echocardiogram. The overproduction of ROS at the time of reperfusion is the critical time when the tissue injuries likely occur, so we initially compared single administration of PVAX (3 mg/kg) 10 minutes before reperfusion with daily injection of PVAX (3 mg/kg per day). Interestingly, single administration of PVAX (3 mg/kg) was comparable to daily injection of PVAX in terms of attenuating cardiac dysfunction ( Figure 4A and 4B) . Therefore, we chose singledose administration of PVAX for our further experiments. Next, the beneficial effects of PVAX after cardiac I/R were compared with poly(lactic-coglycolic acid) (PLGA) nanoparticles, which have no H 2 O 2 responsivess, as a vehicle comparison. Administration of PLGA nanoparticles before reperfusion did not improve I/R-induced cardiac dysfunction when evaluated with PV loop and echocardiography analyses ( Figure 5A  through 5C ). There was no mortality after I/R surgery in both PLGA and PVAX I/R groups. However, significant differences of cardiac function parameters were observed between PVAXand PLGA-treated animals after I/R. In addition, we evaluated infarct size 24 hours after I/R. Consistent with cardiac function evaluation, PVAX nanoparticles significantly reduced the infarct size compared with the PLGA group (48.7AE4.2 vs 14.5AE2.1, P<0.05) (Figure 5D through 5F ).
Cell death and inflammation are important mechanisms involved in cardiac I/R injury. To determine whether the beneficial effects of PVAX nanoparticles are associated with their antiapoptotic and anti-inflammatory activities, we examined the level of apoptosis and inflammation after I/R. PVAX significantly reduced caspase-3 activation and the TUNELpositive cells after I/R compared to the PLGA-treated group ( Figure 6A and 6B ). In addition, PVAX significantly decreased TNF-a and MCP-1 mRNA expressions compared to I/R in PLGA mice (Figure 6C through 6E) . These results indicate that PVAX effectively prevents I/R-induced damage by inhibiting inflammation and apoptosis.
Effects of PVAX on NOX-Induced ROS Generation After Cardiac I/R Recent studies show that NOX-derived ROS plays a pivotal role in cardiac I/R. The increased level of NOX activity/ expression and NOX-dependent ROS production influence several key components of cardiac remodeling, such as myocyte hypertrophy, contractile dysfunction, apoptosis, and fibrosis. 19 To investigate antioxidant activities of PVAX, heart tissues were stained with DHE as a fluorescent marker of ROS. A number of DHE-positive cells were observed in a PLGA I/R group, indicating that I/R injury induced a large generation of ROS. PVAX nanoparticles effectively reduced the generation of ROS caused by I/R ( Figure 7A ). We also investigated the effects of PVAX nanoparticles on the expression of NOX2 and NOX4 24 hours after reperfusion. The levels of NOX2 and NOX4 were elevated after I/R ( Figure 7B through 7D) . However, PVAX nanoparticles significantly reduced the levels of NOX2 and NOX4 compared to PLGA nanoparticles. These results suggest that the reduction of ROS production is attributed to the blockade of NOX2 and NOX4 expression.
Discussion
Although mechanisms of cardiac I/R injury are complex, ROS are major initiators of myocardial damage during I/R. With an elevated level of ROS, cells experience oxidative stress, which then could lead to irreversible damages due to proinflammatory cytokine release, apoptosis, and interstitial fibrosis. is an important pathogenic mechanism of I/R-induced tissue damage through an increase in proinflammatory cytokines such as TNF-a, through activation of p38 MAPK. 20 Excessive ROS after reperfusion also resulted in a marked increase in infarct size, and counteracting the ROS generation reduced the infarct size by up to 50%. 6 Thus, great efforts have been made to develop therapeutic strategies to attenuate I/R injury by suppressing ROS generation and inflammation. Antioxidant nanoparticles formulated from cerium, yttrium, and platinum have been reported to protect against the progression of cardiac dysfunction and remodeling by attenuation of myocardial oxidative stress and inflammatory processes, although there are concerns regarding their toxicity. [24] [25] [26] Nanoparticle-based drug delivery systems have also been developed for targeted delivery of antioxidant therapeutics to reduce infarct volumes and provide sufficient cardioprotective effects during acute myocardial infarction. 10, 27 However, various antioxidant strategies failed to reveal their beneficial effects in the clinical setting, and their therapeutic effects were not clearly elucidated. Ineffectiveness of antioxidant therapy could be explained by various reasons, such as incorrect dosing, dosing frequency, late administration, and inappropriate biomarkers of oxidative damage. However, one of the most likely reasons for the failure of antioxidant strategies for I/R injury could be the lack of interactions between the therapeutic antioxidant and the specific ROS driving the pathological conditions. 8 In this context, scavenging of overproduced H 2 O 2 in the site of oxidative stress is a logical strategy for effective treatment of myocardial I/R injury. In this present study we evaluated the potential of PVAX nanoparticles, which are rapidly activated by H 2 O 2 , to exert potent antioxidant, anti-inflammatory, and antiapoptotic activities during myocardial I/R. PVAX nanoparticles dramatically reduced the ROS-mediated oxidative stress and effectively attenuated I/R injury with reduction of infarct size and improvement of cardiac function. The present study also demonstrated that PVAX nanoparticles effectively blocked NOX-derived ROS overproduction. It is well known that NOX2 and NOX4, electron-transporting membrane enzymes, are major components of the NOX isoforms that produce ROS, particularly superoxide anions and H 2 O 2 , in heart. 28 NOX2 is involved in cardiac remodeling after myocardial infarction, whereas NOX4 is a critical mediator of mitochondrial oxidative stress and mitochondrial dysfunction during heart failure. 29, 30 Previous studies reported that I/R induced significant increases in the levels of NOX2 and NOX4 expression. 31 In addition, knockdown of NOX2 or NOX4 led to a significant decrease in the infarct size accompanied with decrease in cardiomyocyte apoptosis after I/R. We found that PVAX nanoparticles significantly reduced the level of NOX2 and NOX4 expression, which favors the reduction in ROS generation after I/R. The down-regulation of NOX2 and NOX4 may not reflect a true decrease in the activity of the NOXs to generate ROS. However, previous study showed that down-regulation of a single NOX is sufficient to achieve a >50% reduction of ROS. 31 Altogether, blocking the undesirable actions of NOXs with PVAX nanoparticles could be a logical therapeutic strategy for treating oxidative stress-related pathologies such as I/R injury and neurodegenerative and metabolic diseases. 
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